Roche Drug T-DM1 Outdoes Herceptin With Chemotherapy
By Rob Waters - Oct 8, 2010 3:02 PM ET Tweet (1)LinkedIn Share
Roche Holding AG said its two-drug treatment combining an anticancer agent with Herceptin, the company’s $5.27-billion breast cancer drug, was about as effective as, and caused fewer side effects than, Herceptin with chemotherapy.
The results, presented at the European Society for Medical Oncology meeting in Milan, were the first to measure the effectiveness of Roche’s experimental drug called trastuzumab- DM1 as an initial therapy in patients with a particular subtype of breast cancer. T-DM1 is a member of a new class of experimental drugs called antibody-drug conjugates that combine antibodies and anticancer drugs.
Showing posts with label European Society for Medical Oncology. Show all posts
Showing posts with label European Society for Medical Oncology. Show all posts
10/10/10
Roche Promotes Lung Cancer Therapies, ArQule
Roche drugs point to personalized lung cancer care
(Reuters) - Roche's experimental drug MetMab and its established product Tarceva showed impressive results in lung cancer trials on Saturday, highlighting how treating the disease is becoming much more focused.
Cancer experts meeting Milan said personalized treatment, first seen in breast cancer, was now emerging as a major theme in lung cancer. The shift could reduce the use of less targeted drugs, including Roche's own top-selling Avastin.
10/8/10
Roche and Immunogen Develop Highly Targeted Specific Cancer Drugs
Image via WikipediaArticles Today about Roche's partnership with ImmunoGen on TDM-1. TDM-1 is a highly targeted cancer drug for Breast Cancer.
The data from the TDM-1 phase II study in front-line breast cancer patients are early and very preliminary, but also encouraging because they suggest TDM-1 may be the next-generation successor to Herceptin that Roche has been looking for.
ImmunoGen, as Roche's partner on TDM-1, stands to profit as well if the drug is approved and successful.
Subscribe to:
Posts (Atom)